{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:05:22Z","timestamp":1793106322510,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:00:00Z","timestamp":1540339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:00:00Z","timestamp":1540339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\u2018Targeted\u2019 or \u2018biological\u2019 cancer treatments rely on differential gene expression between normal tissue and cancer, and genetic changes that render tumour cells especially sensitive to the agent being applied. Problems exist with the application of many agents as a result of damage to local tissues, tumour evolution and treatment resistance, or through systemic toxicity. Hence, there is a therapeutic need to uncover specific clinical targets which enhance the efficacy of cancer treatment whilst minimising the risk to healthy tissues. T-LAK cell-originated protein kinase (TOPK) is a MAPKK-like kinase which plays a role in cell cycle regulation and mitotic progression. As a consequence, TOPK expression is minimal in differentiated cells, although its overexpression is a pathophysiological feature of many tumours. Hence, TOPK has garnered interest as a cancer-specific biomarker and biochemical target with the potential to enhance cancer therapy whilst causing minimal harm to normal tissues. Small molecule inhibitors of TOPK have produced encouraging results as a stand-alone treatment in vitro and in vivo, and are expected to advance into clinical trials in the near future. In this review, we present the current literature pertaining to TOPK as a potential clinical target and describe the progress made in uncovering its role in tumour development. Firstly, we describe the functional role of TOPK as a pro-oncogenic kinase, followed by a discussion of its potential as a target for the treatment of cancers with high-TOPK expression. Next, we provide an overview of the current preclinical progress in TOPK inhibitor discovery and development, with respect to future adaptation for clinical use.<\/jats:p>","DOI":"10.1038\/s41419-018-1131-7","type":"journal-article","created":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T06:31:26Z","timestamp":1540362686000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9437-0253","authenticated-orcid":false,"given":"Katharine J.","family":"Herbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remko","family":"Prevo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Pirovano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff S.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,24]]},"reference":[{"key":"1131_CR1","doi-asserted-by":"publisher","first-page":"21525","DOI":"10.1074\/jbc.M909629199","volume":"275","author":"Y Abe","year":"2000","unstructured":"Abe, Y., Matsumoto, S., Kito, K. & Ueda, N. Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-originated protein kinase, specifically expressed in the testis and activated lymphoid cells. J. Biol. Chem. 275, 21525\u201321531 (2000).","journal-title":"J. Biol. Chem."},{"key":"1131_CR2","doi-asserted-by":"publisher","first-page":"5186","DOI":"10.1158\/0008-5472.CAN-06-4506","volume":"67","author":"SM Oh","year":"2007","unstructured":"Oh, S. M. et al. T-lymphokine-activated killer cell-originated protein kinase functions as a positive regulator of c-Jun-NH2-kinase 1 signaling and H-Ras-induced cell transformation. Cancer Res. 67, 5186\u20135194 (2007).","journal-title":"Cancer Res."},{"key":"1131_CR3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1053\/j.gastro.2007.04.048","volume":"133","author":"F Zhu","year":"2007","unstructured":"Zhu, F. et al. Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells. Gastroenterology 133, 219\u2013231 (2007).","journal-title":"Gastroenterology"},{"key":"1131_CR4","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.cellsig.2010.05.006","volume":"22","author":"E Aksamitiene","year":"2010","unstructured":"Aksamitiene, E., Kholodenko, B. N., Kolch, W., Hoek, J. B. & Kiyatkin, A. PI3K\/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells. Cell. Signal. 22, 1369\u20131378 (2010).","journal-title":"Cell. Signal."},{"key":"1131_CR5","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1038\/sj.onc.1210142","volume":"26","author":"V Ayllon","year":"2007","unstructured":"Ayllon, V. & O\u2019Connor, R. PBK\/TOPK promotes tumour cell proliferation through p38 MAPK activity and regulation of the DNA damage response. Oncogene 26, 3451\u20133461 (2007).","journal-title":"Oncogene"},{"key":"1131_CR6","doi-asserted-by":"publisher","first-page":"15594","DOI":"10.18632\/oncotarget.3709","volume":"6","author":"JD Brown-Clay","year":"2015","unstructured":"Brown-Clay, J. D. et al. PBK\/TOPK enhances aggressive phenotype in prostate cancer via beta-catenin-TCF\/LEF-mediated matrix metalloproteinases production and invasion. Oncotarget 6, 15594\u201315609 (2015).","journal-title":"Oncotarget"},{"key":"1131_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-015-0398-x","volume":"14","author":"M Joel","year":"2015","unstructured":"Joel, M. et al. Targeting PBK\/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo. Mol. Cancer 14, 121 (2015).","journal-title":"Mol. Cancer"},{"key":"1131_CR8","doi-asserted-by":"crossref","first-page":"17652","DOI":"10.18632\/oncotarget.7755","volume":"7","author":"T Kato","year":"2016","unstructured":"Kato, T. et al. Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells. Oncotarget 7, 17652\u201317664 (2016).","journal-title":"Oncotarget"},{"key":"1131_CR9","doi-asserted-by":"publisher","first-page":"29601","DOI":"10.1074\/jbc.M111.225813","volume":"286","author":"S Li","year":"2011","unstructured":"Li, S. et al. T-LAK cell-originated protein kinase (TOPK) phosphorylation of MKP1 protein prevents solar ultraviolet light-induced inflammation through inhibition of the p38 protein signaling pathway. J. Biol. Chem. 286, 29601\u201329609 (2011).","journal-title":"J. Biol. Chem."},{"key":"1131_CR10","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ijbiomac.2015.08.048","volume":"81","author":"JH Chen","year":"2015","unstructured":"Chen, J. H. et al. Overexpression of PDZ-binding kinase confers malignant phenotype in prostate cancer via the regulation of E2F1. Int. J. Biol. Macromol. 81, 615\u2013623 (2015).","journal-title":"Int. J. Biol. Macromol."},{"key":"1131_CR11","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1006\/bcmd.2001.0452","volume":"27","author":"M Simons-Evelyn","year":"2001","unstructured":"Simons-Evelyn, M. et al. PBK\/TOPK is a novel mitotic kinase which is upregulated in Burkitt\u2019s lymphoma and other highly proliferative malignant cells. Blood. Cells Mol. Dis. 27, 825\u2013829 (2001).","journal-title":"Blood. Cells Mol. Dis."},{"key":"1131_CR12","doi-asserted-by":"publisher","first-page":"5167","DOI":"10.1073\/pnas.090102397","volume":"97","author":"S Gaudet","year":"2000","unstructured":"Gaudet, S., Branton, D. & Lue, R. A. Characterization of PDZ-binding kinase, a mitotic kinase. Proc. Natl Acad. Sci. USA 97, 5167\u20135172 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1131_CR13","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/j.1440-169X.2005.00834.x","volume":"47","author":"T Fujibuchi","year":"2005","unstructured":"Fujibuchi, T. et al. Expression and phosphorylation of TOPK during spermatogenesis. Dev. Growth Differ. 47, 637\u2013644 (2005).","journal-title":"Dev. Growth Differ."},{"key":"1131_CR14","doi-asserted-by":"publisher","first-page":"10773","DOI":"10.1523\/JNEUROSCI.3207-05.2005","volume":"25","author":"JD Dougherty","year":"2005","unstructured":"Dougherty, J. D. et al. PBK\/TOPK, a proliferating neural progenitor-specific mitogen-activated protein kinase kinase. J. Neurosci. 25, 10773\u201310785 (2005).","journal-title":"J. Neurosci."},{"key":"1131_CR15","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.bbrc.2004.10.133","volume":"325","author":"S Matsumoto","year":"2004","unstructured":"Matsumoto, S. et al. Characterization of a MAPKK-like protein kinase TOPK. Biochem. Biophys. Res. Commun. 325, 997\u20131004 (2004).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1131_CR16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jmb.2007.04.067","volume":"370","author":"Y Abe","year":"2007","unstructured":"Abe, Y. et al. A mitotic kinase TOPK enhances Cdk1\/cyclin B1-dependent phosphorylation of PRC1 and promotes cytokinesis. J. Mol. Biol. 370, 231\u2013245 (2007).","journal-title":"J. Mol. Biol."},{"key":"1131_CR17","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1349-7006.2009.01400.x","volume":"101","author":"JH Park","year":"2010","unstructured":"Park, J. H., Nishidate, T., Nakamura, Y. & Katagiri, T. Critical roles of T-LAK cell-originated protein kinase in cytokinesis. Cancer Sci. 101, 403\u2013411 (2010).","journal-title":"Cancer Sci."},{"key":"1131_CR18","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.18632\/oncotarget.2735","volume":"6","author":"R Rizkallah","year":"2015","unstructured":"Rizkallah, R., Batsomboon, P., Dudley, G. B. & Hurt, M. M. Identification of the oncogenic kinase TOPK\/PBK as a master mitotic regulator of C2H2 zinc finger proteins. Oncotarget 6, 1446\u20131461 (2015).","journal-title":"Oncotarget"},{"key":"1131_CR19","doi-asserted-by":"publisher","first-page":"9186","DOI":"10.1158\/0008-5472.CAN-06-1601","volume":"66","author":"JH Park","year":"2006","unstructured":"Park, J. H., Lin, M. L., Nishidate, T., Nakamura, Y. & Katagiri, T. PDZ-binding kinase\/T-LAK cell-originated protein kinase, a putative cancer\/testis antigen with an oncogenic activity in breast cancer. Cancer Res. 66, 9186\u20139195 (2006).","journal-title":"Cancer Res."},{"key":"1131_CR20","first-page":"4822","volume":"15","author":"Y Chai","year":"2018","unstructured":"Chai, Y. et al. MicroRNA-216b-3p inhibits lung adenocarcinoma cell growth via regulating PDZ binding kinase\/T-LAK-cell-originated protein kinase. Exp. Ther. Med. 15, 4822\u20134828 (2018).","journal-title":"Exp. Ther. Med."},{"key":"1131_CR21","doi-asserted-by":"crossref","unstructured":"Yang, Y. F., et al. PDZ binding kinase, regulated by FoxM1, enhances malignant phenotype via activation of beta-Catenin signaling in hepatocellular carcinoma. Oncotarget\u00a08, 47195-47205 (2017).","DOI":"10.18632\/oncotarget.17587"},{"key":"1131_CR22","doi-asserted-by":"crossref","first-page":"26604","DOI":"10.18632\/oncotarget.8445","volume":"7","author":"MY Wang","year":"2016","unstructured":"Wang, M. Y. et al. PDZ binding kinase (PBK) is a theranostic target for nasopharyngeal carcinoma: driving tumor growth via ROS signaling and correlating with patient survival. Oncotarget 7, 26604\u201326616 (2016).","journal-title":"Oncotarget"},{"key":"1131_CR23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.cellsig.2017.08.001","volume":"39","author":"S Stauffer","year":"2017","unstructured":"Stauffer, S. et al. CDK1-mediated mitotic phosphorylation of PBK is involved in cytokinesis and inhibits its oncogenic activity. Cell. Signal. 39, 74\u201383 (2017).","journal-title":"Cell. Signal."},{"key":"1131_CR24","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1158\/0008-5472.CAN-10-1735","volume":"71","author":"I Shats","year":"2011","unstructured":"Shats, I. et al. Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Res. 71, 1772\u20131780 (2011).","journal-title":"Cancer Res."},{"key":"1131_CR25","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1089\/scd.2015.0374","volume":"25","author":"IH Bellayr","year":"2016","unstructured":"Bellayr, I. H., Marklein, R. A., Lo Surdo, J. L., Bauer, S. R. & Puri, R. K. Identification of predictive gene markers for multipotent stromal cell proliferation. Stem Cells Dev. 25, 861\u2013873 (2016).","journal-title":"Stem Cells Dev."},{"key":"1131_CR26","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/cas.13160","volume":"108","author":"JH Park","year":"2017","unstructured":"Park, J. H. et al. TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer. Cancer Sci. 108, 488\u2013496 (2017).","journal-title":"Cancer Sci."},{"key":"1131_CR27","doi-asserted-by":"publisher","first-page":"259ra145","DOI":"10.1126\/scitranslmed.3010277","volume":"6","author":"Y Matsuo","year":"2014","unstructured":"Matsuo, Y. et al. TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis. Sci. Transl. Med. 6, 259ra145 (2014).","journal-title":"Sci. Transl. Med."},{"key":"1131_CR28","doi-asserted-by":"publisher","first-page":"33410","DOI":"10.18632\/oncotarget.5418","volume":"6","author":"H Alachkar","year":"2015","unstructured":"Alachkar, H. et al. T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia. Oncotarget 6, 33410\u201333425 (2015).","journal-title":"Oncotarget"},{"key":"1131_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ebiom.2017.04.003","volume":"18","author":"TA Zykova","year":"2017","unstructured":"Zykova, T. A. et al. The T-LAK cell-originated protein kinase signal pathway promotes colorectal cancer metastasis. EBioMedicine 18, 73\u201382 (2017).","journal-title":"EBioMedicine"},{"key":"1131_CR30","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1158\/1535-7163.MCT-17-0628","volume":"17","author":"T Zykova","year":"2018","unstructured":"Zykova, T. et al. Targeting PRPK function blocks colon cancer metastasis. Mol. Cancer Ther. 17, 1101\u20131113 (2018).","journal-title":"Mol. Cancer Ther."},{"issue":"42","key":"1131_CR31","doi-asserted-by":"publisher","first-page":"5633","DOI":"10.1038\/s41388-018-0350-9","volume":"37","author":"Eunmiri Roh","year":"2018","unstructured":"Roh, E., et al. Targeting PRPK and TOPK for skin cancer prevention and therapy. Oncogene\u00a037, 5633\u20135647 (2018).","journal-title":"Oncogene"},{"key":"1131_CR32","doi-asserted-by":"publisher","first-page":"6884","DOI":"10.1158\/1078-0432.CCR-06-0410","volume":"12","author":"TA Zykova","year":"2006","unstructured":"Zykova, T. A. et al. Lymphokine-activated killer T-cell-originated protein kinase phosphorylation of histone H2AX prevents arsenite-induced apoptosis in RPMI7951 melanoma cells. Clin. Cancer Res. 12, 6884\u20136893 (2006).","journal-title":"Clin. Cancer Res."},{"key":"1131_CR33","doi-asserted-by":"publisher","first-page":"29138","DOI":"10.1074\/jbc.M110.135905","volume":"285","author":"TA Zykova","year":"2010","unstructured":"Zykova, T. A. et al. T-LAK cell-originated protein kinase (TOPK) phosphorylation of Prx1 at Ser-32 prevents UVB-induced apoptosis in RPMI7951 melanoma cells through the regulation of Prx1 peroxidase activity. J. Biol. Chem. 285, 29138\u201329146 (2010).","journal-title":"J. Biol. Chem."},{"key":"1131_CR34","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3390\/ijms17030267","volume":"17","author":"G Sun","year":"2016","unstructured":"Sun, G. et al. The protective role of the TOPK\/PBK pathway in myocardial ischemia\/reperfusion and H(2)O(2)-induced injury in H9C2 cardiomyocytes. Int. J. Mol. Sci. 17, 267 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"1131_CR35","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1161\/STROKEAHA.114.006135","volume":"45","author":"H Zhao","year":"2014","unstructured":"Zhao, H. et al. Ischemic postconditioning relieves cerebral ischemia and reperfusion injury through activating T-LAK cell-originated protein kinase\/protein kinase B pathway in rats. Stroke 45, 2417\u20132424 (2014).","journal-title":"Stroke"},{"key":"1131_CR36","doi-asserted-by":"publisher","first-page":"5464","DOI":"10.1038\/onc.2010.275","volume":"29","author":"F Hu","year":"2010","unstructured":"Hu, F. et al. PBK\/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21. Oncogene 29, 5464\u20135474 (2010).","journal-title":"Oncogene"},{"key":"1131_CR37","first-page":"830-834","volume":"391","author":"HR Kwon","year":"2010","unstructured":"Kwon, H. R., Lee, K. W., Dong, Z., Lee, K. B. & Oh, S. M. Requirement of T-lymphokine-activated killer cell-originated protein kinase for TRAIL resistance of human HeLa cervical cancer cells. Biochem. Biophys. Res. Commun. 391, 830-834 (2010).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1131_CR38","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1074\/jbc.M112.422170","volume":"288","author":"JH Park","year":"2013","unstructured":"Park, J. H., Yoon, D. S., Choi, H. J., Hahm, D. H. & Oh, S. M. Phosphorylation of IkappaBalpha at serine 32 by T-lymphokine-activated killer cell-originated protein kinase is essential for chemoresistance against doxorubicin in cervical cancer cells. J. Biol. Chem. 288, 3585\u20133593 (2013).","journal-title":"J. Biol. Chem."},{"key":"1131_CR39","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.bbrc.2007.04.125","volume":"358","author":"AK Nandi","year":"2007","unstructured":"Nandi, A. K., Ford, T., Fleksher, D., Neuman, B. & Rapoport, A. P. Attenuation of DNA damage checkpoint by PBK, a novel mitotic kinase, involves protein-protein interaction with tumor suppressor. Biochem. Biophys. Res. Commun. 358, 181\u2013188 (2007). p53.","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1131_CR40","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/bjc.2017.197","volume":"117","author":"G Pirovano","year":"2017","unstructured":"Pirovano, G. et al. TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy. Br. J. Cancer 117, 503\u2013512 (2017).","journal-title":"Br. J. Cancer"},{"key":"1131_CR41","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1158\/0008-5472.CAN-11-3851","volume":"72","author":"DJ Kim","year":"2012","unstructured":"Kim, D. J. et al. Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth. Cancer Res. 72, 3060\u20133068 (2012).","journal-title":"Cancer Res."},{"issue":"9","key":"1131_CR42","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1158\/1535-7163.MCT-17-0212","volume":"16","author":"Ge Gao","year":"2017","unstructured":"Gao, G., et al. ADA-07 suppresses solar ultraviolet-induced skin carcinogenesis by directly inhibiting TOPK. Mol Cancer Ther\u00a016, 1\u201312 (2017).","journal-title":"Molecular Cancer Therapeutics"},{"key":"1131_CR43","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.bbrc.2017.03.162","volume":"488","author":"J Zou","year":"2017","unstructured":"Zou, J., Kuang, W., Hu, J. & Rao, H. miR-216b promotes cell growth and enhances chemosensitivity of colorectal cancer by suppressing PDZ-binding kinase. Biochem. Biophys. Res. Commun. 488, 247\u2013252 (2017).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1131_CR44","doi-asserted-by":"publisher","first-page":"6110","DOI":"10.1158\/1078-0432.CCR-16-0207","volume":"22","author":"Y Ikeda","year":"2016","unstructured":"Ikeda, Y. et al. T-LAK cell-originated protein kinase (TOPK) as a prognostic factor and a potential therapeutic target in ovarian cancer. Clin. Cancer Res. 22, 6110\u20136117 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1131_CR45","doi-asserted-by":"crossref","unstructured":"Pirovano, G., et al. [18F]FE-OTS964: a small molecule targeting TOPK for in vivo PET imaging in a glioblastoma xenograft model. Mol. Imaging Biol. 2018 (in press).","DOI":"10.1007\/s11307-018-1288-6"},{"key":"1131_CR46","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","volume":"26","author":"PJ Roberts","year":"2007","unstructured":"Roberts, P. J. & Der, C. J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26, 3291\u20133310 (2007).","journal-title":"Oncogene"},{"key":"1131_CR47","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1517\/14728210903282760","volume":"15","author":"JA McCubrey","year":"2010","unstructured":"McCubrey, J. A. et al. Emerging MEK inhibitors. Expert. Opin. Emerg. Drugs 15, 203\u2013223 (2010).","journal-title":"Expert. Opin. Emerg. Drugs"},{"key":"1131_CR48","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.canlet.2009.01.022","volume":"283","author":"C Montagut","year":"2009","unstructured":"Montagut, C. & Settleman, J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 283, 125\u2013134 (2009).","journal-title":"Cancer Lett."},{"key":"1131_CR49","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrd4504","volume":"14","author":"U Asghar","year":"2015","unstructured":"Asghar, U., Witkiewicz, A. K., Turner, N. C. & Knudsen, E. S. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat. Rev. Drug. Discov. 14, 130\u2013146 (2015).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1131_CR50","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nrc.2016.138","volume":"17","author":"T Otto","year":"2017","unstructured":"Otto, T. & Sicinski, P. Cell cycle proteins as promising targets in cancer therapy. Nat. Rev. Cancer 17, 93\u2013115 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"1131_CR51","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0960-9822(99)80164-X","volume":"9","author":"S Giroux","year":"1999","unstructured":"Giroux, S. et al. Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr. Biol. 9, 369\u2013372 (1999).","journal-title":"Curr. Biol."},{"key":"1131_CR52","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/nrm2718","volume":"10","author":"AJ Holland","year":"2009","unstructured":"Holland, A. J. & Cleveland, D. W. Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nat. Rev. Mol. Cell Biol. 10, 478\u2013487 (2009).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1131_CR53","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/nrc1714","volume":"5","author":"GJ Kops","year":"2005","unstructured":"Kops, G. J., Weaver, B. A. & Cleveland, D. W. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat. Rev. Cancer 5, 773\u2013785 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"1131_CR54","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ccr.2005.06.011","volume":"8","author":"BA Weaver","year":"2005","unstructured":"Weaver, B. A. & Cleveland, D. W. Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell. 8, 7\u201312 (2005).","journal-title":"Cancer Cell."},{"key":"1131_CR55","doi-asserted-by":"crossref","first-page":"146282","DOI":"10.1155\/2015\/146282","volume":"2015","author":"MM Mc Gee","year":"2015","unstructured":"Mc Gee, M. M. Targeting the mitotic catastrophe signaling pathway in cancer. Mediat. Inflamm. 2015, 146282 (2015).","journal-title":"Mediat. Inflamm."},{"key":"1131_CR56","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.4161\/cc.10.19.17619","volume":"10","author":"R Rizkallah","year":"2011","unstructured":"Rizkallah, R., Alexander, K. E. & Hurt, M. M. Global mitotic phosphorylation of C2H2 zinc finger protein linker peptides. Cell Cycle 10, 3327\u20133336 (2011).","journal-title":"Cell Cycle"},{"key":"1131_CR57","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/pros.20910","volume":"69","author":"DE Hansel","year":"2009","unstructured":"Hansel, D. E. et al. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate 69, 603\u2013609 (2009).","journal-title":"Prostate"},{"key":"1131_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-9-153","volume":"9","author":"T Shiraishi","year":"2011","unstructured":"Shiraishi, T. et al. Cancer\/testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. J. Transl. Med. 9, 153 (2011).","journal-title":"J. Transl. Med."},{"key":"1131_CR59","doi-asserted-by":"crossref","first-page":"12392","DOI":"10.18632\/oncotarget.3630","volume":"6","author":"H Sun","year":"2015","unstructured":"Sun, H. et al. TOPK is highly expressed in circulating tumor cells, enabling metastasis of prostate cancer. Oncotarget 6, 12392\u201312404 (2015).","journal-title":"Oncotarget"},{"key":"1131_CR60","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.humpath.2009.05.016","volume":"41","author":"F He","year":"2010","unstructured":"He, F. et al. PBK\/TOPK in the differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma and its involvement in prognosis of human cholangiocarcinoma. Hum. Pathol. 41, 415\u2013424 (2010).","journal-title":"Hum. Pathol."},{"key":"1131_CR61","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/cbf.2964","volume":"31","author":"F Chen","year":"2013","unstructured":"Chen, F. et al. T-LAK cell-originated protein kinase is essential for the proliferation of hepatocellular carcinoma SMMC-7721 cells. Cell. Biochem. Funct. 31, 736\u2013742 (2013).","journal-title":"Cell. Biochem. Funct."},{"key":"1131_CR62","doi-asserted-by":"publisher","first-page":"E1007","DOI":"10.3390\/ijms17071007","volume":"17","author":"CF Chang","year":"2016","unstructured":"Chang, C. F. et al. PBK\/TOPK expression predicts prognosis in oral cancer. Int. J. Mol. Sci. 17, E1007 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"1131_CR63","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.humpath.2014.07.026","volume":"46","author":"B Lei","year":"2015","unstructured":"Lei, B. et al. PBK\/TOPK expression correlates with mutant p53 and affects patients\u2019 prognosis and cell proliferation and viability in lung adenocarcinoma. Hum. Pathol. 46, 217\u2013224 (2015).","journal-title":"Hum. Pathol."},{"key":"1131_CR64","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.bcmd.2003.10.004","volume":"32","author":"A Nandi","year":"2004","unstructured":"Nandi, A., Tidwell, M., Karp, J. & Rapoport, A. P. Protein expression of PDZ-binding kinase is up-regulated in hematologic malignancies and strongly down-regulated during terminal differentiation of HL-60 leukemic cells. Blood Cells Mol. Dis. 32, 240\u2013245 (2004).","journal-title":"Blood Cells Mol. Dis."},{"key":"1131_CR65","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/bjc.2016.394","volume":"116","author":"T Ohashi","year":"2017","unstructured":"Ohashi, T. et al. Overexpression of PBK\/TOPK relates to tumour malignant potential and poor outcome of gastric carcinoma. Br. J. Cancer 116, 218\u2013226 (2017).","journal-title":"Br. J. Cancer"},{"key":"1131_CR66","doi-asserted-by":"publisher","first-page":"6457","DOI":"10.21873\/anticanres.11244","volume":"36","author":"T Ohashi","year":"2016","unstructured":"Ohashi, T. et al. Overexpression of PBK\/TOPK contributes to tumor development and poor outcome of esophageal squamous cell carcinoma. Anticancer Res. 36, 6457\u20136466 (2016).","journal-title":"Anticancer Res."},{"key":"1131_CR67","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1038\/modpathol.2011.96","volume":"24","author":"T Vlajnic","year":"2011","unstructured":"Vlajnic, T. et al. VEGFA gene locus (6p12) amplification identifies a small but highly aggressive subgroup of colorectal cancer [corrected] patients. Mod. Pathol. 24, 1404\u20131412 (2011).","journal-title":"Mod. Pathol."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1131-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1131-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1131-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T09:58:35Z","timestamp":1672653515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1131-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,24]]},"references-count":67,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,11]]}},"alternative-id":["1131"],"URL":"https:\/\/doi.org\/10.1038\/s41419-018-1131-7","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,24]]},"assertion":[{"value":"3 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"1089"}}